Numerous studies have demonstrated CD47's overexpression in various tumor types, including myeloma, leiomyosarcoma, acute lymphocytic leukemia, non-lymphoma, Hodgkin's breast cancer, osteosarcoma, and head and neck squamous cell carcinoma [75]. This evidence concerns the gene CD47 and neoplasm.